Orgenesis Inc (ORGS): Koefisien rega marang pendapatan

Orgenesis Inc. (ORGS) is developing the POCare network to optimize cell production costs through CDMO contracts. Historical P/S dynamics demonstrate the market valuation of revenue, where the 15.10 level reflects the current multiple. The strategy of deploying mobile laboratories within clinics accelerates personalized treatment, although high debt and platform scaling challenges are currently weakening the company's competitive advantages.

The P/S multiple compares market capitalization to annual revenue, determining the extent to which investors are overpaying for every dollar of the business's gross income. By analyzing the price-to-sales multiple history, one can assess how closely market expectations for the implementation of decentralized cell therapy in clinics and institutes align with the actual monetization rates of Orgenesis Inc. technological solutions.